Tildipirosin
Overview[edit]
Tildipirosin is a macrolide antibiotic used primarily in veterinary medicine. It is effective against a range of bacterial infections in animals, particularly in cattle and swine. Tildipirosin is known for its long-acting properties, which make it suitable for treating respiratory diseases in livestock.
Mechanism of Action[edit]
Tildipirosin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby preventing the translocation of peptides. This action effectively halts the growth of susceptible bacteria, making it a bacteriostatic agent.
Pharmacokinetics[edit]
Tildipirosin is administered via subcutaneous injection in cattle and intramuscular injection in swine. It is characterized by rapid absorption and a long half-life, which allows for sustained therapeutic concentrations in the target tissues. The drug is primarily excreted through the bile and feces.
Clinical Uses[edit]
Tildipirosin is used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease (SRD) in pigs. It is effective against pathogens such as Mannheimia haemolytica, Pasteurella multocida, and Haemophilus parasuis.
Safety and Side Effects[edit]
Tildipirosin is generally well-tolerated in animals. However, some adverse effects may occur, including mild injection site reactions. It is important to adhere to the recommended dosage and withdrawal periods to ensure food safety.
Regulatory Status[edit]
Tildipirosin is approved for use in many countries, including the United States and the European Union. It is regulated by agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
